Myasthenia gravis, castleman disease, pemphigus, and anti-phospholipid syndrome

Muscle and Nerve

Volumn 47, Issue 3, 2013, Pages 447-451

  Jakubíková, Michala ^a   Piťha, Jiří ^a   Latta, Jan ^b   Ehler, Edvard ^b   Schutzner, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF PARDUBICE   (Czech Republic)

Author keywords

Anti phospholipid syndrome; Castleman disease; Interleukin 6; Myasthenia gravis; Pemphigus vulgaris

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NEOSTIGMINE; PYRIDOSTIGMINE; RITUXIMAB;

ABDOMINAL PAIN; ABDOMINAL TUMOR; ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN ISCHEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE SEVERITY; DRUG DOSE INCREASE; DYSARTHRIA; DYSPHAGIA; FATIGUE; HUMAN; HUMAN TISSUE; LAPAROTOMY; LIMB WEAKNESS; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYASTHENIA GRAVIS; NERVE STIMULATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC PEMPHIGUS; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PTOSIS; SEPSIS; THYMECTOMY; ULNAR NERVE;

ABDOMINAL NEOPLASMS; ADULT; ANTIPHOSPHOLIPID SYNDROME; BLEPHAROPTOSIS; DIPLOPIA; FATAL OUTCOME; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROLOGIC EXAMINATION; PEMPHIGUS; STROKE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874242370     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23657     Document Type: Article

References (27)

1. Castleman B, Ivesron L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822-830.
2. Cesarman E. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Rec Res Cancer Res 2002;159:27-37.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-1280.
4. Nishimoto N, Sasai M, Shima Y, Masashi N, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
5. Dispenzieri A, Kyle AR, Lacy QM, Rajkumar VS, Therneau MT, Larson RD, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496-2506.
6. Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM. Case report: Castleman disease in association with POEMS. Am J Med Sci 1994;307:112-114.
7. Abdel-Reheim FA, Koss W, Rappaport ES, Arber DA. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Arch Pathol Lab Med 1996;120:91-96.
8. Caneppele S, Picart N, Bayle-Lebey P, Paul J-L, Irsutti M, Oksman F, et al. Paraneoplastic pemphigus associated with Castleman's tumour. Clin Exp Dermatos 2000;25:219-221.
9. Fujimoto W, Kanehiro A, Kuwamoto-Hara K, Saitoh M, Nakakita T, Amagai M, et al. Paraneoplastic pemphigus associated with Castleman disease and asymptomatic bronchiolitis obliterans. Eur J Dermatol 2002;12:355-359.
10. Menenakos C, Braumann C, Hartmann J, Jacobi CA. Retroperitoneal Castleman's tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J Surg Oncol 2007;5:45.
11. De Marchi G, De Vita S, Fabris M, Scott CA, Ferraccioli G. Systemic connective tissue disease complicated by Castleman disease: report of a case and review of the literature. Haematologica 2004;89:ECR03.
12. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-1367.
13. Conti-Fine MB, Milani M, Kaminski JH. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-2854.
14. Liu R, La Cava A, Bai FX, Jee Y, Price M, Campagnolo ID, et al. Cooperation of invariant NKT cells and CD4 + CD25 + T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005;175:7898-7904.
15. Cohen-Kaminski S, Delattre RM, Devergne O, Klingel-Schmitt I, Emilie D, Galanaud P, et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann NY Acad Sci 1993;681:97-99.
16. Endo S, Hasegawa T, Sato Y, Otani S, Saito N, Tetsuka K, et al. Inhibition of IL-6 overproduction by steroid treatment before transsternal thymectomy for myasthenia gravis: does it help stabilize perioperative condition? Eur J Neurol 2005;12:768-773.
17. Takatsu K. Cytokines involved in B-cell differentiation and their sites of action. Proc Soc Exp Biol Med 1997;215:121-133.
18. Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011;36:135-141.
19. Epson HE. Extrathoracic angiofollicular lymphoid hyperplasia with coincidental myasthenia gravis. Cancer 1973;21:241-245.
20. Pasaoglu I, Dogan R, Topcu M, Gungen Y. Multicentric angiofollicular lymph-node hyperplasia associated with myasthenia gravis. Thorac Cardiovasc Surg 1994;42:253-256.
21. Day JR, Bew D, Ali M, Dina R, Smith PL. Castleman disease associated with myasthenia gravis. Ann Thorac Surg 2003;75:1648-1650.
22. Chorzelski T, Hashimoto T, Maciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman disease, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol 1999;41:393-400.
23. Yadav S, Lesic C. Extra thoracic Castleman disease associated with myasthenia gravis. Indian J Thorac Cardiovasc Surg 2010;26:275-276.
24. Du QM, Liu H, Diss CT, Ye H, Hamouni AR, Dupin N, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-2136.
25. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-250.
26. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41:375-378.
27. Deng C, Goluczko E, Tuzun E, Yang H, Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and reduced C3 production. J Immunol 2002;169:1077-1083.